Australia adds GSK's Shingrix to National Immunization Program

The Australian business of British drugmaker GSK (LSE: GSK) has secured a positive listing decision from authorities for its shingles vaccine.

Affecting around one in three adults, shingles can be a painful and potentially debilitating condition, caused by the chickenpox virus later in life.

Shingles also comes with the risk of certain complications after the disease has passed, the most common being post-herpetic neuralgia (PHN), a burning pain in nerves and skin.